Optimizing Antithyroid Drug Duration in Graves’ Disease with Low TRAb: Evidence for Shorter Therapy
Highlight
This study evaluates relapse outcomes following shorter versus standard antithyroid drug (ATD) therapy in Graves’ disease patients with lower baseline thyrotropin receptor antibody (TRAb) levels. It finds that ATD courses shorter than 12 months yield relapse rates broadly comparable to the guideline-recommended 12-18 months, a finding that supports TRAb-guided individualized treatment duration.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.